<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709018</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-15-2-0090</org_study_id>
    <nct_id>NCT02709018</nct_id>
  </id_info>
  <brief_title>A Controlled Trial of Losartan in Posttraumatic Stress Disorder</brief_title>
  <acronym>LOSe-PTSD</acronym>
  <official_title>Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry M. Jackson Foundation, Walter Reed National Military Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation for Atlanta Veterans Education and Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if losartan, an angiotensin receptor blocker&#xD;
      (ARB), is safe and effective in the treatment of posttraumatic stress disorder (PTSD)&#xD;
      symptoms. The study is also intended to determine if certain genetic markers are useful in&#xD;
      predicting PTSD symptom reduction with losartan. Approximately 160 subjects with chronic PTSD&#xD;
      ages 18-65 will participate in this study across five sites. Subjects will be assigned by&#xD;
      chance to take either flexibly dosed losartan (up to a maximum dosage of 100 mg) or placebo&#xD;
      (which resembles the study drug but has no active ingredients), once a day for 10 weeks.&#xD;
      Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have&#xD;
      a superior response to losartan on PTSD symptoms compared to T carriers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are limited current treatments available for PTSD, and the only FDA-approved&#xD;
      medications are SSRIs, which were empirically found to be somewhat helpful. Losartan provides&#xD;
      a potentially important and exciting development in that it is readily available, safe,&#xD;
      inexpensive (available as a generic drug), and has a neurobiological mechanism based on&#xD;
      recent exciting discoveries, as outlined below. This proposal is designed to test, in a&#xD;
      multisite RCT, this novel, mechanistically-determined, safe and well-tolerated, potentially&#xD;
      powerful treatment for PTSD symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2016</start_date>
  <completion_date type="Actual">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm.</measure>
    <time_frame>10 weeks</time_frame>
    <description>Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week.&#xD;
The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan.</measure>
    <time_frame>10 weeks</time_frame>
    <description>The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan flexibly dosed from 25-100 mg per day over 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo flexibly dosed from 25-100 mg per day over 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>Angiotensin receptor blocker (ARB)</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Below is a synopsis of relevant eligibility criteria. For details please refer to the&#xD;
        protocol by contacting the Principal Investigator]&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Subject must be a man or woman between 18 and 70 years of age, inclusive.&#xD;
&#xD;
          2. Subjects must have a primary DSM-5 diagnosis of Posttraumatic Stress Disorder.&#xD;
&#xD;
          3. Subjects must have a Clinical Administered PTSD Scale for PTSD (CAPS-5) â‰¥ 25&#xD;
             persistent at Screening for at least 3 months duration.&#xD;
&#xD;
          4. Subject must be willing and able to adhere to the prohibitions and restrictions&#xD;
             specified in this protocol.&#xD;
&#xD;
          5. Subject must be willing and able to fill out self-administered questionnaires.&#xD;
&#xD;
          6. Subject must be able to be compliant with self-administration of medication.&#xD;
&#xD;
          7. Subject must be able to swallow the study medication whole with aid of water.&#xD;
&#xD;
          8. Subject must sign an informed consent document indicating that they understand the&#xD;
             purpose of and procedures required for the study and are willing to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects who have current or imminent risk of suicide as assessed by the&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS) at each study visit.&#xD;
&#xD;
          2. Subject with active psychosis.&#xD;
&#xD;
          3. Subject has a history of moderate or severe drug or alcohol use disorder according to&#xD;
             DSM-5 criteria within 3 months before screening.&#xD;
&#xD;
          4. Subject has a history of allergy to losartan or other angiotensin receptor blockers&#xD;
             (ARBs).&#xD;
&#xD;
          5. Subject has a medical illness likely to result in imminent hospitalization or for&#xD;
             which treatments are contraindicated based on lab results, medical history and&#xD;
             physical exam.&#xD;
&#xD;
          6. Subject has serious cognitive impairment felt likely to interfere with the ability to&#xD;
             participate meaningfully in the study. Participants with mild to moderate traumatic&#xD;
             brain injury (TBI) will not be excluded from the study. Only those who evidence&#xD;
             significant cognitive impairment at Screening (as evidenced by confusion, inability to&#xD;
             track discussion or answer questions, or other clear and significant indicators of&#xD;
             cognitive impairment) will be excluded.&#xD;
&#xD;
          7. Concurrent ACE Inhibitors or Angiotensin Receptor Blockers or Prazosin; patients on&#xD;
             other antihypertensives may be enrolled if, after consultation with their prescribing&#xD;
             physician, it is determined that the addition of losartan would not be&#xD;
             contraindicated.&#xD;
&#xD;
          8. Concurrent antidepressants or antipsychotics. Subjects, who have elected, in&#xD;
             consultation with their health care provider, to discontinue any antidepressants or&#xD;
             antipsychotics, must be off the medications for a minimum of 2 weeks prior to study&#xD;
             randomization. Stable bedtime doses of sleep agents (e.g., trazodone â‰¤ 200mg;&#xD;
             eszopiclone; zolpidem; lorazepam) will be allowed as long as the dose has been stable&#xD;
             for at least 2 weeks prior to study randomization. Benzodiazepines taken for other&#xD;
             than sleep are not permitted.&#xD;
&#xD;
          9. Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant.&#xD;
&#xD;
         10. Subject is unable to comply with the study-specific requirements&#xD;
&#xD;
         11. Subjects with abnormal liver, renal or EKG findings as determined by physician.&#xD;
&#xD;
         12. Subject exhibits clinically-significant hypertension as determined by medical&#xD;
             evaluation and/or BP &gt; 190/100.&#xD;
&#xD;
         13. Systolic Blood Pressure (SBP) &lt; 90mmHg.&#xD;
&#xD;
         14. Liver function Tests (LFT's) &gt; 2 times the upper limit of normal.&#xD;
&#xD;
         15. Patients with Chronic Kidney Disease 4, as determined by history, baseline labs&#xD;
             (including eGFR &lt; 45ml/minute) and evaluation by a physician will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray B Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kerry J Ressler, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>McLean Hospital and Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Khoury NM, Marvar PJ, Gillespie CF, Wingo A, Schwartz A, Bradley B, Kramer M, Ressler KJ. The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry. 2012 Jun;73(6):849-55. doi: 10.4088/JCP.11m07316. Epub 2012 May 1.</citation>
    <PMID>22687631</PMID>
  </reference>
  <reference>
    <citation>Krause EG, de Kloet AD, Scott KA, Flak JN, Jones K, Smeltzer MD, Ulrich-Lai YM, Woods SC, Wilson SP, Reagan LP, Herman JP, Sakai RR. Blood-borne angiotensin II acts in the brain to influence behavioral and endocrine responses to psychogenic stress. J Neurosci. 2011 Oct 19;31(42):15009-15. doi: 10.1523/JNEUROSCI.0892-11.2011.</citation>
    <PMID>22016534</PMID>
  </reference>
  <reference>
    <citation>Llano LÃ³pez LH, Caif F, GarcÃ­a S, Fraile M, Landa AI, Baiardi G, Lafuente JV, Braszko JJ, Bregonzio C, Gargiulo PA. Anxiolytic-like effect of losartan injected into amygdala of the acutely stressed rats. Pharmacol Rep. 2012;64(1):54-63.</citation>
    <PMID>22580520</PMID>
  </reference>
  <reference>
    <citation>Saavedra JM, SÃ¡nchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology. 2011 Jan;36(1):1-18. doi: 10.1016/j.psyneuen.2010.10.001. Epub 2010 Oct 29. Review.</citation>
    <PMID>21035950</PMID>
  </reference>
  <reference>
    <citation>Nylocks KM, Michopoulos V, Rothbaum AO, Almli L, Gillespie CF, Wingo A, Schwartz AC, Habib L, Gamwell KL, Marvar PJ, Bradley B, Ressler KJ. An angiotensin-converting enzyme (ACE) polymorphism may mitigate the effects of angiotensin-pathway medications on posttraumatic stress symptoms. Am J Med Genet B Neuropsychiatr Genet. 2015 Jun;168B(4):307-15. doi: 10.1002/ajmg.b.32313. Epub 2015 Apr 29.</citation>
    <PMID>25921615</PMID>
  </reference>
  <reference>
    <citation>Hurt RC, Garrett JC, Keifer OP Jr, Linares A, Couling L, Speth RC, Ressler KJ, Marvar PJ. Angiotensin type 1a receptors on corticotropin-releasing factor neurons contribute to the expression of conditioned fear. Genes Brain Behav. 2015 Sep;14(7):526-33. doi: 10.1111/gbb.12235. Epub 2015 Aug 25.</citation>
    <PMID>26257395</PMID>
  </reference>
  <reference>
    <citation>Marvar PJ, Goodman J, Fuchs S, Choi DC, Banerjee S, Ressler KJ. Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. Biol Psychiatry. 2014 Jun 1;75(11):864-72. doi: 10.1016/j.biopsych.2013.08.024. Epub 2013 Oct 4.</citation>
    <PMID>24094510</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <results_first_submitted>February 2, 2021</results_first_submitted>
  <results_first_submitted_qc>February 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2021</results_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Murray B. Stein</investigator_full_name>
    <investigator_title>Professor of Psychiatry, Family Medicine and Public Health</investigator_title>
  </responsible_party>
  <keyword>posttraumatic stress disorder</keyword>
  <keyword>losartan</keyword>
  <keyword>angiotensin receptor blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02709018/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan</title>
          <description>Losartan flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
losartan: Angiotensin receptor blocker (ARB)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary outcome (CAPS-5) was analyzed using an MMRM (mixed model repeated measures) approach based on a modified intent-to-treat (mITT) population, defined as randomized subjects who initiated treatment and had both a baseline and at least one post-baseline outcome score during the blinded phase of the study (Week 10). Participants from the mITT population who were included in the MMRM model also required both a baseline and at least one post-baseline CAPS-5 score.</population>
      <group_list>
        <group group_id="B1">
          <title>Losartan</title>
          <description>Losartan flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
losartan: Angiotensin receptor blocker (ARB)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="12.3"/>
                    <measurement group_id="B2" value="35.5" spread="12.6"/>
                    <measurement group_id="B3" value="36.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAPS-5 Total</title>
          <description>The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score as administered here reflects the sum of the 20 DSM-5 PTSD items, each scored 0-4. Range of the scale is 0-80. Higher scores indicate greater severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="10.3"/>
                    <measurement group_id="B2" value="34.2" spread="10.0"/>
                    <measurement group_id="B3" value="33.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm.</title>
        <description>Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week.&#xD;
The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.</description>
        <time_frame>10 weeks</time_frame>
        <population>Modified Intent to Treat (mITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
losartan: Angiotensin receptor blocker (ARB)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm.</title>
          <description>Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week.&#xD;
The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.</description>
          <population>Modified Intent to Treat (mITT) Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.96" lower_limit="-18.86" upper_limit="-13.06"/>
                    <measurement group_id="O2" value="-16.89" lower_limit="-19.81" upper_limit="-13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan.</title>
        <description>The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.</description>
        <time_frame>10 weeks</time_frame>
        <population>Subjects on Losartan Arm</population>
        <group_list>
          <group group_id="O1">
            <title>CC Homozygotes on Losartan</title>
            <description>CC Homozygotes on Losartan</description>
          </group>
          <group group_id="O2">
            <title>T Carriers on Losartan</title>
            <description>T Carriers on Losartan</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan.</title>
          <description>The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.</description>
          <population>Subjects on Losartan Arm</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="10.1"/>
                    <measurement group_id="O2" value="15.8" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Weeks (Study Duration)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>Losartan flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
losartan: Angiotensin receptor blocker (ARB)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo flexibly dosed from 25-100 mg per day over 10 weeks&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <description>Neurosyphilis not reported at baseline but reported during study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Cataplexy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="75"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Murray B. Stein MD, MPH</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>858-534-6451</phone>
      <email>mstein@health.ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

